Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri ATG-F4
- Development stage
- Phase 2
- Lead developer
- Yuhan
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus reuteri ATG-F4 (LT-002) is an investigational live biotherapeutic product (LBP) consisting of a specific probiotic bacterial strain originally isolated from the human gut. Developed by AtoGEN Co., Ltd., it is currently in Phase 2 clinical development for the treatment of chemotherapy-induced cachexia in patients with advanced colorectal or pancreatic cancer receiving oxaliplatin-based chemotherapy. The strain's mechanism of action involves the gut-muscle and gut-brain axes; it promotes muscle protein synthesis by activating the mTOR signaling pathway and inhibits muscle degradation by downregulating the muscle atrophy factor MuRF1 (TRIM63). Furthermore, ATG-F4 modulates the gut microbiota composition, increasing the production of short-chain fatty acids (SCFAs) such as butyrate and acetate, and has demonstrated the ability to modulate dopamine and serotonin levels, suggesting potential applications in mental health disorders like depression and anxiety.
- Other names
- Lactobacillus reuteri ATG-F4L. reuteri ATG-F4
02
Targets
TRIM63 (E3 ubiquitin-protein ligase TRIM63)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on lactobacillus reuteri ATG-F4.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri ATG-F4.